Navigation Links
Determining Valuations in Challenging Times

In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies. The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the latest report from PharmaVentures, provides expert guidance on critical aspects of deal-making, including valuations and royalty rate calculations.

Oxford, UK (PRWEB) November 5, 2008 -- In the current financial climate, the availability of venture capital will simply dry up, particularly for start-up biotech companies and those desperate for additional funding. This leaves many vulnerable companies with a critical need for cash, and their key to survival in the short-term will be deal-making with larger pharmaceutical and biotech companies. The market is now reacting to this depleted cash availability and so the terms of licensing deals are turning back in favour of those cash-rich pharmaceutical companies.

"For biotechs, protecting cash flow is key to survival, which means that licensing terms have become more crucial than ever before", claims Fintan Walton, CEO of PharmaVentures, a leading transactions firm. In fact, managing both financial as well as clinical risk will be vitally important according to the recently published report from PharmaVentures, The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector. "The adoption of the correct valuation models can enable companies to derive better value from their deal-making in these financially challenging times. The Report sets out to provide essential assessment through the most powerful methodologies available, selected case studies and PharmaVentures consultants' experience in deal making advisory services."

Nigel Borshell, Editor of the Report, says, "In these important times, the Report explodes some of the myths of valuations and royalty rates calculations, highlights what you should factor in to your own calculations and explains how best to generate useful royalty rate outcomes. It does this by providing key case histories, deal analysis, and opinion leader comment all relating to the quest for better more useable valuation data." A significant part of the content has been formulated by leveraging PharmaVentures' 16 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal-making.

Topics covered in the Report include:

  • Clear guidance on the best methodologies to use when calculating Valuations and Royalty Rates to assist with vital decision making
  • Opinions and advice from leading industry deal makers on how to calculate Royalty Rates
  • Contextual information - The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: "What do royalties mean in terms of value?" and "Where do royalties fit within the deal?"
  • More case studies - PharmaVentures highlights the issues and pitfalls

PharmaVentures has previously published three successful reports on royalty rates in the pharmaceutical industry. "However, this time we conducted even more extensive surveys and the 2009 Edition represents a complete rewrite", says Fintan Walton, "and, judging by the excellent response from companies worldwide, it will, in short time, become the industry standard reference on the topic". The new Royalty Rate Report is published under PharmaVentures' imprint, PharmaDeals®.

According to Fintan Walton: "This report complements PharmaVentures' insight and expertise to the industry on these issues particularly through our advisory services and our pan media offerings, PharmaDeals and PharmaTelevision."

Notes to Editors:

About PharmaVentures
PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of publishing products that include databases, analysis tools, and reports as well as PharmaTelevision, the industry's first dedicated online TV channel. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

About the Report
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector.
A Report by PharmaVentures, Edited by Nigel Borshell
ISBN 978-0-9558821-3-5
Available in print and in electronic format
Table of Contents and Sample Pages
Order Form

Related Video from PharmaTelevision

PharmaVentures: Valuation methods and trends in licensing deals

Windows Media Player

For further information about the Report and other PharmaDeals databases and publications, including ordering, please contact:
Lisa Holloway
Magdalen Centre
Oxford Science Park

T: +44 (0) 1865 784 177

For information about PharmaTelevision, please contact:
Deborah Harris
Magdalen Centre
Oxford Science Park
T: +44 (0)1865 784 162


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
2. CSHL scientists make progress in determining how the brain selectively interprets sound
3. New method proposed for determining which patients should get treatment for colorectal cancer
4. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
5. Determining genetic signature of lung tumors can help guide treatment
6. Fitness a Key Element in Determining Male Diabetics Longevity
7. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer
8. Past Earnings Play Role in Determining SSDI Benefits
9. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
10. National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety
11. Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health
Post Your Comments:
Related Image:
Determining Valuations in Challenging Times 
(Date:11/25/2015)... ... 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna industry, ... far-infrared saunas. , For traditional saunas, Finnleo is offering 20% off ... and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown trees. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... FL (PRWEB) , ... November 25, 2015 , ... ... center, is encouraging people across the country to celebrate their sobriety and show ... people to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of Botto ... by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented ... IL App (2d) 130884WC. , According to court documents, Adcock testified that on May ...
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 25, 2015 The hope ... repeated failure of IVF cycles. After failure of over ... and had lost all hopes that she would be able to conceive ever. ... child conceived after failure of over 15 IVF cycles. ... before they decided to take one last attempt with Gaudium IVF ...
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
Breaking Medicine Technology: